NSE ScannerHDFC Mutual Fund · Equity · Sectoral / Thematic · Direct plan
HDFC Pharma and Healthcare Fund - Direct Plan - Growth
₹21.952NAV on 30 Oct 2026Expense ratio 1.03%
29 Oct 2025NAV low 16.83 · high 22.89+23.1%
In plain words
Over 3 years it returned +30.5% a year, against +7.4% for its benchmark index.
Its worst fall from a peak in the last 3 years was -14.9%.
On 3-year return it ranks 3 of 139 funds in Sectoral / Thematic.
A monthly SIP over 3 years ended ₹10,578 higher in the direct plan than the regular plan, because of the lower expense ratio.
Past returns, not a promise of future returns or a recommendation.
Returns vs benchmark
| Period | Fund | Benchmark |
|---|---|---|
| 1 month | +0.0% | +1.9% |
| 3 months | +0.8% | -5.1% |
| 6 months | +16.7% | -3.2% |
| 1 year | +23.1% | -10.2% |
| 3 years (yearly) | +30.5% | +7.4% |
| Since start (yearly) | +29.3% | +11.2% |
Monthly SIP of ₹10,000
| Period | Invested | Value now | Yearly return |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,39,640 | +27.6% |
| 3 years | ₹3,60,000 | ₹5,16,368 | +23.7% |
Other plan of this fund: HDFC Pharma and Healthcare Fund - Regular Plan - Growth